Current disease‐modifying treatment of multiple sclerosis
J Derwenskus - Mount Sinai Journal of Medicine: A Journal of …, 2011 - Wiley Online Library
The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …
modifying therapy. This changed the management of multiple sclerosis from treating acute …
Current and future disease‐modifying therapies in multiple sclerosis
SY Lim, CS Constantinescu - International journal of clinical …, 2010 - Wiley Online Library
The development of disease‐modifying therapies (DMT) in multiple sclerosis (MS) has
rapidly evolved over the last few years and continues to do so. Prior to the United States …
rapidly evolved over the last few years and continues to do so. Prior to the United States …
New and emerging treatment options for multiple sclerosis
CH Polman, BMJ Uitdehaag - The Lancet Neurology, 2003 - thelancet.com
Background The use of interferon beta and glatiramer acetate for the treatment of multiple
sclerosis (MS) has, to some extent, changed the course of the disease. The annual relapse …
sclerosis (MS) has, to some extent, changed the course of the disease. The annual relapse …
[HTML][HTML] Disease modifying agents for multiple sclerosis
O Hilas, PN Patel, S Lam - The open neurology journal, 2010 - ncbi.nlm.nih.gov
Objective: To summarize major clinical trials which evaluate the efficacy and safety data of
approved disease modifying agents for the treatment of various types of multiple sclerosis …
approved disease modifying agents for the treatment of various types of multiple sclerosis …
[PDF][PDF] Drug class review: Disease-modifying drugs for multiple sclerosis
B Smith, S Carson, R Fu, M McDonagh, T Dana… - Oregon Health & …, 2010 - ohsu.edu
Purpose We compared the effectiveness and safety of disease-modifying drugs for the
treatment of multiple sclerosis: Glatiramer acetate (Copaxone®), interferon beta-1a …
treatment of multiple sclerosis: Glatiramer acetate (Copaxone®), interferon beta-1a …
Current disease-modifying therapies in multiple sclerosis
BC Kieseier, HP Hartung - Seminars in neurology, 2003 - thieme-connect.com
In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of
relapsing-remitting multiple sclerosis (RRMS) has been established. Interferon beta has also …
relapsing-remitting multiple sclerosis (RRMS) has been established. Interferon beta has also …
Current and emerging treatment of multiple sclerosis.
FM Hart, J Bainbridge - The American journal of managed care, 2016 - europepmc.org
The treatment of multiple sclerosis (MS) falls into 3 categories: treatment of exacerbations,
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …
Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes
O Katrych, TM Simone, S Azad… - CNS & Neurological …, 2009 - ingentaconnect.com
Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and
neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of …
neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of …
What is new in the treatment of multiple sclerosis?
B Weinstock-Guttman, LD Jacobs - Drugs, 2000 - Springer
Multiple sclerosis (MS) is considered an autoimmune disease associated with immune
activity directed against central nervous system antigens. Based on this concept …
activity directed against central nervous system antigens. Based on this concept …
Multiple sclerosis: pathogenesis and treatment
I Loma, R Heyman - Current neuropharmacology, 2011 - ingentaconnect.com
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …
central nervous system. It affects approximately 400,000 people in the United States and …